Linvas Tablet

Introduction

Linvas is a prescription medication that contains the active ingredient Saroglitazar. It is commonly used to treat certain conditions related to lipid metabolism and diabetes.

Uses

Linvas is prescribed to help manage lipid abnormalities, such as high cholesterol and triglyceride levels, in patients with type 2 diabetes mellitus. It can also be used as an adjunct to diet and exercise to improve glycemic control in patients with diabetes who have inadequate blood sugar control.

Dosage and Administration

The dosage of Linvas will be determined by your healthcare provider based on your specific condition and medical history. It is usually taken orally, with or without food, once daily.

Follow your doctor’s instructions regarding the dosage and timing of this medication. Do not exceed the recommended dose or alter the dosage without consulting your healthcare provider.

Mechanism of Action

Saroglitazar, the active ingredient in Linvas, works by activating a specific receptor in the body called PPAR (peroxisome proliferator-activated receptor). This helps regulate lipid and glucose metabolism, leading to improved lipid profiles and glycemic control in patients with lipid abnormalities and diabetes.

Side Effects

Common side effects may include headache, dizziness, nausea, vomiting, stomach discomfort, and muscle pain. These side effects are usually mild and temporary.

However, be aware of potential serious side effects that may occur. These can include liver problems, including jaundice (yellowing of the skin and eyes), dark urine, and persistent abdominal pain. If you experience any of these serious side effects, seek immediate medical attention.

Drug Interactions

Linvas may interact with other medications, including certain antidiabetic medications, fibrates, and some cholesterol-lowering drugs. Inform your healthcare provider about all the medications you are currently taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

Precautions

Before starting Linvas, inform your healthcare provider about any medical conditions you have, especially liver disease or any history of liver problems.

You should also inform your doctor about any allergies or sensitivities you have, as well as any other medications you are taking, including supplements and herbal products.

Linvas is not recommended for use in pregnant or breastfeeding women, as the safety of the medication in these populations has not been established.

Storage

Linvas should be stored at room temperature, away from direct sunlight and moisture. Keep it out of the reach of children and pets. Do not use the medication if it has reached its expiration date or if the packaging is damaged.

Patient Tips

• Take Linvas exactly as prescribed by your healthcare provider. Do not skip doses or stop taking the medication without consulting your doctor.
• Follow a healthy diet and exercise routine as recommended by your healthcare provider to optimize the benefits of Linvas.
• If you experience any bothersome or persistent side effects, contact your healthcare provider for further guidance.
• Keep all your appointments with your doctor for regular check-ups and monitoring of your condition.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-alpha/gamma Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19. [Accessed 1 Jun. 2024] Available at:
• Joshi SR. Saroglitazar for the treatment of dyslipidemia in diabetic patients. Expert Opin Pharmacother. 2015 Mar;16(4):597-606. doi: 10.1517/14656566.2015.1009894. [Accessed 17 Jun. 2024] Available at:
• Siddiqui MS, Parmar D, Sheikh F, Sarin SK, Cisneros L, Gawrieh S, Momin T, Duseja A, Sanyal AJ. Saroglitazar, a Dual PPAR alpha/gamma Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis. Clin Gastroenterol Hepatol. 2023 Sep;21(10):2597-2605.e2. doi: 10.1016/j.cgh.2023.01.018. Epub 2023 Jan 31. [Accessed 15 Jun. 2024] Available at:
• Francque S. Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator-Activated Receptor Story Goes On! Hepatology. 2021 Oct;74(4):1730-1733. doi: 10.1002/hep.32024. Epub 2021 Aug 30. [Accessed 23 Jun. 2024] Available at: